Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Brief Somalia.
Press releases published on September 5, 2025
uniQure Announces Initial AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease
~ All patients in the first cohort achieved between 27- to 208-fold increases in α-Gal A activity relative to mean normal level ~ ~ All patients in first cohort discontinued enzyme replacement therapy ~ ~ Preliminary data show AMT-191 has a manageable …
Entrada Therapeutics Announces Recipients of Third Annual DREAMS Grant Program
-- The 2025 DREAMS Grant Program awards $50,000 each to two non-profit organizations working to advance equity, accessibility and inclusion for those living with Duchenne in the U.S., EU or U.K. -- -- Announced in advance of World Duchenne Awareness Day on …
OrthoPediatrics Corp. Announces Distribution Agreement with MY01 Inc.
WARSAW, Ind., Sept. 05, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics announced today a new distribution partnership with MY01, an innovative medical technology …
CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months
- Robust 24-month complete response (CR) rate of 41.8% observed for cretostimogene monotherapy in patients with high-risk non-muscle invasive bladder cancer (NMIBC) who are unresponsive to Bacillus Calmette Guerin (BCG) treatment - - 90% of 12-month …
Medicenna to Participate at the H.C. Wainwright 27th Annual Global Investment Conference
TORONTO and HOUSTON, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage cancer immunotherapy company focused on the development of Superkines, announced today that Dr. …
AAVantgarde presents updated positive clinical data from its AAVB-081 program for Usher 1B at EURetina 2025
MILAN, Sept. 05, 2025 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company developing next-generation gene therapies for inherited retinal diseases, today announced the presentation of updated clinical data from the …
Akari Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
BOSTON and LONDON, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced that Abizer Gaslightwala, President and Chief …
Biodesix to Participate in Lake Street Capital Markets’ 9th Annual Best Ideas Growth (BIG9) Conference
LOUISVILLE, Colo., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced Robin Cowie, Chief Financial Officer, will host in-person 1x1 investor meetings at Lake Street Capital Markets’ 9th …
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that on September …
RHEA Essentials Inositol Returns for Hormonal Support
VILNIUS, Lithuania, Sept. 05, 2025 (GLOBE NEWSWIRE) -- After months of being sold out, RHEA Essentials Inositol is finally returning, and people are already talking about it. Known for supporting hormonal balance, metabolic health, and emotional well-being …
Tensive annuncia aggiornamenti clinici positivi che evidenziano il potenziale del dispositivo REGENERA™ / SOFTAG™ per la ricostruzione del seno post-lumpectomia
I dati clinici provenienti da due studi in corso su pazienti sottoposte a lumpectomia confermano il profilo di sicurezza e i crescenti benefici prestazionali del dispositivo Gli obiettivi primari di sicurezza e secondari di efficacia sono stati raggiunti …
Tensive provides positive clinical updates highlighting potential of REGENERA™ / SOFTAG™ device to transform post-cancer breast reconstruction
Clinical data from two ongoing trials in patients undergoing lumpectomy confirm strong safety profile and growing performance benefits of device Primary safety and secondary performance objectives met in interim analysis of 25 patients in pivotal trial, …
MAPS Statement on FDA’s Public Release of Complete Response Letter for MDMA-assisted Therapy
SAN JOSE, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- In August 2024, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to Lykos Therapeutics, declining to approve MDMA-assisted therapy for Posttraumatic Stress Disorder ( …
HUTCHMED Highlights Clinical Data to be Presented at the 2025 World Conference of Lung Cancer and the CSCO Annual Meeting 2025
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 05, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be …